T-cell/histiocyte-rich large B-cell lymphoma with initial involvement of the spleen: case report
DOI:
https://doi.org/10.35509/01239015.1010Keywords:
Lymphoma, neoplasms, splenic neoplasms, drug therapy, splenectomyAbstract
T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is a rare histological subtype within diffuse large B-cell lymphomas (DLBCL); it constitutes almost 0.1% of all lymphomas. The available knowledge on THRLBCL is scarce and mainly derived from published cases and case series. We present the case of a 69-year-old man who underwent laparoscopic splenectomy due to a splenic mass and constitutional symptoms. The immunohistochemistry of the lesion showed a THRLBCL. Two months later, lymph node, intestinal, and soft tissue involvement was detected. He received six cycles of chemotherapy with dose-adjusted rituximab, etoposide, prednisolone, vincristine, cyclophosphamide, and doxorubicin (DA-R-EPOCH) regimen with an excellent response and complete disease regression.
Author Biographies
Yeni Alexandra Arroyave-Guerrero, Departamento de Cirugía, Clínica La Estancia, Popayán, Colombia.
1. Departamento de Cirugía, Clínica La Estancia, Popayán, Colombia.
David Emanuel Manzano-Astudillo, Estudiante de pregrado en Medicina, Universidad del Cauca, Popayán, Colombia.
2. Estudiante de pregrado en Medicina, Universidad del Cauca, Popayán, Colombia.
Guillermo Vallejo-Vallecilla, Programa de Cirugía Hepatobiliar, Clínica La Estancia, Popayán, Colombia.
3. Programa de Cirugía Hepatobiliar, Clínica La Estancia, Popayán, Colombia.
4. Departamento de Ciencias Quirúrgicas, Universidad del Cauca, Popayán, Colombia.
References
Müller DA, Torres MA, Soyano AE, Soyano A. Tratamiento del linfoma difuso de células B grandes (LDCBG) en estadios avanzados. Gac Méd Caracas. 2017;125(4):276-98. Disponible en: https://ve.scielo.org/scielo.php?script=sci_arttext&pid=S0367-47622017000400003
Cruz-Benítez L, Pérez-Reyna JD, González-Muïler GM. Linfoma esplénico difuso de células grandes estirpe B. Reporte de caso. Gac Mex Oncol. 2017;16(6):344-50. http://dx.doi.org/10.24875/j.gamo.M17000096
Guevara NM, Jaramillo PE, Gaviria LM. Linfoma B difuso de células grandes: factores pronósticos en la era del rituximab. Iatreia. 2013;26(3):302-12. Disponible en: https://www.redalyc.org/pdf/1805/180528412006.pdf
Martínez A, Balsalobre MD, García MA. Linfoma primario de bazo difuso de células grandes B doble hit: un subtipo de mal pronóstico. Rev Col Cancerol. 2018;22(4):143-5. https://doi.org/10.1016/j.rccan.2018.08.002
Ahmad TY, Al Houri HN, Jomaa S, Assad W, Addeen SZ. Primary splenic T-cell/histiocyte-rich B-cell lymphoma in a patient with recurrent hairy cell leukemia: a case report. Oxf Med Case Reports. 2022;2022(11):383-7. https://doi.org/10.1093/omcr/omac123
Zheng SM, Zhou DJ, Wang YX, Zhang Y, Xue HL, Wang HQ, et al. Pancreatic t/histiocyte-rich large B-cell lymphoma: a case report and review of literature. World J Gastroenterol. 2017;23(24):4467-72. https://doi.org/10.3748/wjg.v23.i24.4467
Samueli B, Nalbandyan K, Benharroch D, Levi I. Splenic micronodular T-cell/histiocyte-rich large B-cell lymphoma: the corticosteroid pretreatment hypothesis. Acta haematologica. 145(3):310-7. https://doi.org/10.1159/000520791
Xu J, Wu X, Reddy V. T cell/histiocyte-rich large B cell lymphoma of the thymus: a diagnostic pitfall. Case Rep Hematol. 2016, Artículo ID2942564, 7 p. https://doi.org/10.1155/2016/2942594
Mas-Medina V, Rodríguez-Rodríguez M, Cuéllar-Armas A, Más-Herrera R, Gómez-Mutis A. Linfoma primario de bazo. Presentación de un caso. Gac Méd Espirit. 2013;15(3):317-23. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1608-89212013000300007
Li M, Zhang L, Wu N, Huang W, Lv N. Imaging findings of primary splenic lymphoma: a review of 17 cases in which diagnosis was made at splenectomy. PLoS One. 2013;8(11):e80264. https://doi.org/10.1371/journal.pone.0080264
Vasconcelos LC, Muñío JE, Hernández C, Pérez D. Evolución de los linfomas no Hodgkin de células grandes según el índice pronóstico internacional. Rev cubana med. 2005;44(5-6):1-9. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75232005000500005
Major A, Smith SM. DA-R-EPOCH vs R-CHOP in DLBCL: How do we choose? Clin Adv Hematol Oncol. 2021;19(11):698-709. PMID: 34807015
Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance/CALGB 50303. J Clin Oncol. 2019;37(21):1790-9. http://ascopubs.org/doi/full/10.1200/JCO.18.01994
Dholaria B, Moreno YA, Diehl N, Spaulding AC, Visscher S, Tun HW, et al. Cost analysis of R-CHOP versus dose-adjusted R-EPOCH in treatment of diffuse large B-cell lymphoma with high-risk features. Clin Hematol Int. 2020;2(3):117-24. https://doi.org/10.2991/chi.d.200410.001
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Revista Colombiana de Cancerología
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Todos los derechos reservados.
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
